Search results
Results from the WOW.Com Content Network
"Indiana University Department of Medicine Clinical Pharmacology Drug Interactions Flockhart Table ™". "INHIBITORS, INDUCERS AND SUBSTRATES OF CYTOCHROME P450 ISOZYMES". "The Life Raft Group: Long List of Inhibitors and Inducers of CYP3A4 and CYP2D6". "DRUGBANK Online: Cytochrome P-450 Enzyme Inhibitors".
Strong and moderate CYP3A4 inducers are drugs that decrease the AUC of sensitive substrates of a given pathway where CYP3A4 is involved by ≥80 percent and ≥50 to <80 percent, respectively. [ 83 ] [ 123 ] Weak inducers decrease the AUC by ≥20 to <50 percent.
Pages in category "CYP3A4 inhibitors" The following 96 pages are in this category, out of 96 total. This list may not reflect recent changes. A. Amiodarone; Amlodipine;
Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma. As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of co-administered medicinal products that are metabolized through CYP3A4.
For a list of CYP3A4 inhibitors and inducers, see here.) The strong CYP3A4 inhibitors ketoconazole and erythromycin have been found to increase exposure to dienogest by up to 3-fold, whereas the strong CYP3A4 inducer rifampicin (rifampin) was found to decrease steady-state and area-under-curve concentrations of dienogest by 50% and 80% ...
Nirmatrelvir is a SARS-CoV-2 main protease (M pro, 3CL pro, nsp5 protease) inhibitor while ritonavir is an HIV-1 protease inhibitor and strong CYP3A inhibitor. [ 10 ] [ 19 ] Nirmatrelvir is the main active agent in the formulation, while ritonavir, which inhibits HIV-1 protease , is a strong CYP3A inhibitor : it inhibits the metabolization of ...
Cytochrome P450 inhibitors is a category of agents that inhibit Cytochrome P450. ... CYP3A4 inhibitors (96 P) ... This list may not reflect recent changes. A.
Bedaquiline should not be co-administered with other drugs that are strong inducers or inhibitors of CYP3A4, the liver enzyme responsible for oxidative metabolism of the drug. [3] Co-administration with rifampin, a strong CYP3A4 inducer, results in a 52% decrease in the AUC of the drug. This reduces the exposure of the body to the drug and ...